About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5906504
Allelic
Composition
Lmnatm2.1Gbon/Lmna+
Genetic
Background
involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Lmnatm2.1Gbon mutation (0 available); any Lmna mutation (84 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice die between 35 and 70 weeks of age
• death occurs about 15-20 weeks after reduced fractional shortening

cardiovascular system
• at end stage, degenerative changes are seen in cardiac tissues with disrupted sarcomeres, myofibrillar lysis, vesicular proliferation of sarcomeric reticulum, intracytoplasmic junctions, electron dense residual bodies, and pericellular fibrosis
• large proportion of nuclei in the heart are more elongated and thinner at 10, 30, and 57 weeks of age and these nuclei have enlarged nuclear intermembrane space in young asymptomatic mice
• mice with mild cardiac dysfunction show severe alterations in cardiac nuclei, such as extremely enlarged nuclear intermembrane space, accumulation of large perinuclear vacuoles, or envelope rupture with extravasations of chromatin into the cytoplasm
• atrial enlargement
• increase in left ventricular end-diastolic diameter
• however, no major wall thinning is seen
• at end stage, the left ventricle shows slight fibrosis
• mice exhibit decreased fractional shortening and increased left ventricle end-diastolic diameter indicating dilated cardiomyopathy
• progressive development of cardiac dysfunction from 32 to 70 weeks of age
• decrease in fractional shortening which starts a bit earlier in males than in females
• echocardiography indicates decreased fractional shortening and increased left ventricle end-diastolic diameter without wall thinning
• slight bradycardia is seen at the very end stages of the dilated cardiomyopathy
• higher PR interval is seen at the very end stages of the dilated cardiomyopathy
• QRS complex broadening is seen at the very end stages of the dilated cardiomyopathy
• mice eventually present with congestive heart failure demonstrated by left ventricle hypokinesia and lung edema

homeostasis/metabolism
N
• 57 week old mice do not exhibit metabolic defects
• lung edema in mice with congestive heart failure

muscle
N
• 57 week old mice do not exhibit skeletal muscle defects or skeletal muscle contractile function defects
• at end stage, degenerative changes are seen in cardiac tissues with disrupted sarcomeres, myofibrillar lysis, vesicular proliferation of sarcomeric reticulum, intracytoplasmic junctions, electron dense residual bodies, and pericellular fibrosis
• mice exhibit decreased fractional shortening and increased left ventricle end-diastolic diameter indicating dilated cardiomyopathy
• progressive development of cardiac dysfunction from 32 to 70 weeks of age
• decrease in fractional shortening which starts a bit earlier in males than in females
• cardiac sarcomeres are disrupted at end stage of disease and vesicular proliferation of sarcomeric reticulum is seen

respiratory system
• lung edema in mice with congestive heart failure

growth/size/body

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
dilated cardiomyopathy 1A DOID:0110425 OMIM:115200
J:198526


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/19/2024
MGI 6.24
The Jackson Laboratory